Jiangsu Hengrui Pharmaceuticals revenue and financials
¥47.20Change from previous close: +3.46%Absolute change: +¥1.58
In the fiscal year ended December 2025, Jiangsu Hengrui Pharmaceuticals reported revenue of ¥31.63B (+13.02% year over year). Net income was ¥7.71B, a net margin of 24.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.02%
- 2025 vs 2024
- Net income growth
- +21.69%
- 2025 vs 2024
- Net margin
- 24.4%
- 2024: 22.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 11,235 | 7,423 | 7,644 | 1,265 | — |
| Depreciation and amortization | 845 | 776 | 705 | 578 | — |
| Capital expenditure | -2,962 | -1,969 | -1,484 | -1,992 | — |
| Investing cash flow | -2,741 | -1,912 | 1,222 | 390 | — |
| Financing cash flow | 7,782 | -1,551 | -3,144 | -319 | — |
| Dividends paid | -1,284 | -1,275 | -1,023 | -1,016 | — |
| Debt issued | 1,496 | 800 | 21.1 | 1,260 | — |
| Debt repaid | -1,500 | -800 | -1,281 | — | — |
| Effect of exchange rates | -360 | 7.4 | 12.5 | 80.5 | — |
| Net change in cash | 16,277 | 3,960 | 5,722 | 1,337 | — |
| Free cash flow | 8,273 | 5,454 | 6,160 | -727 | — |